---
layout: default
title: Aceclidine
parent: 僅模型預測 (L5)
nav_order: 65
evidence_level: L5
indication_count: 0
---

# Aceclidine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Aceclidine: Repurposing Evaluation — Insufficient Evidence Pack

## One-Sentence Summary

Aceclidine (DB13262) is a pharmacological compound for which original indication data is not captured in this Evidence Pack.
The TxGNN pipeline returned **no predicted indications** for this drug, and critical data including mechanism of action, safety warnings, and regulatory information are all absent.
This report documents the current data status and outlines the remediation steps required before a repurposing evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No data available |
| Predicted New Indication | No TxGNN predictions returned |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction unavailable; no supporting studies |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No mechanism of action data is available for Aceclidine in this Evidence Pack (Data Gap DG002).
The DrugBank query on 2026-03-24 returned a record (result count: 1), confirming the compound exists in DrugBank under ID DB13262, but MOA details were not extracted into the Evidence Pack.

Without a confirmed MOA and without any TxGNN predicted indications (`predicted_indications: []`), it is not possible to construct a mechanistic rationale linking Aceclidine to any new disease indication at this stage.

A repurposing rationale analysis should be re-attempted once the TxGNN prediction pipeline is re-run and the DrugBank MOA is retrieved.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for any predicted indication, as no predicted indications are available in this Evidence Pack.

---

## Literature Evidence

Currently no related literature available, as no predicted indications are available in this Evidence Pack.

---

## US Market Information

Aceclidine has no NDA filings and is not currently marketed in the United States. No license records are available.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** The TFDA label (warnings and contraindications) was flagged as a Blocking data gap (DG001) and could not be retrieved for this Evidence Pack. The DDI query returned no interactions. All safety fields are currently unpopulated.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Aceclidine is structurally incomplete — the TxGNN pipeline returned zero predicted indications, and two blocking/high-severity data gaps prevent any safety or mechanistic analysis from proceeding.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Retrieve TFDA label PDF and parse warnings/contraindications to unblock the S1 safety screen
- **[High — DG002]** Query DrugBank API to extract the mechanism of action (MOA) for DB13262 and populate `original_moa`
- **[Required]** Re-run the TxGNN prediction pipeline to generate `predicted_indications`; investigate why the current run returned an empty array (possible causes: drug not found in knowledge graph, mapping failure, or filtering threshold too strict)
- **[Recommended]** Confirm original indications via DrugBank `indication` field or published pharmacological references to complete the drug profile before re-evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

